Our radiochemistry team are experts in the development and quality control of radiopharmaceuticals, including a broad spectrum of radionuclides and targeting vectors.
We work closely with sponsors to design robust, reproducible experimental plans, including radiolabeling method development and process development pipelines for in vitro assays, in vivo imaging, biodistribution, dosimetry, radiation toxicity and efficacy studies.
We specialize in the conjugation of small molecules, proteins, peptides, antibodies, cells and ADCs to clinically relevant chelators (e.g., DOTA, NOTA, DFO), optimizing coupling efficiency and preserving biological functionality.
Our team develops and refines radiolabeling protocols to maximize radiochemical yield and specific activity, while minimizing degradation and free radionuclide content. Labeling conditions are customized based on the chelator-radionuclide pair and application requirements.
Using state-of-the-art radio-HPLC and solid-phase extraction methods, we purify radiolabeled products to high chemical and radiochemical purity. Final formulations are tailored for biological assays, small animal models, or downstream applications.
We perform stability assessments in various biological matrices and buffers, supporting product validation for short- and long-term applications. Analytical tools include HPLC, iTLC and gamma counting.
